Developer of first-in-class targeted small molecule therapies designed to provide treatment for solid tumors. The company's drug discovery programs are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors and uses proprietary technology platform to rationally design protein-protein interaction inhibitors, enabling patient to begin treatment more quickly and result in a higher likelihood of a successful treatment.